AMGN News

Latest breaking news and updates for AMGN stock.

Track all markets on TradingView

AMGEN INVESTING MORE THAN HALF A BILLION DOLLARS IN NEW, STATE-OF-THE-ART CENTER FOR SCIENCE AND INNOVATION AT U.S. GLOBAL HEADQUARTERS

(NASDAQ:AMGN) Research and Development Infrastructure Investment Expected to Create Hundreds of U.S. Jobs THOUSAND OAKS, Calif., Sept. 2, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced p...

When is the projected job creation timeline and how might the added headcount impact Amgen’s operating expenses and R&D productivity over the next few years? What competitive advantage does this new science and innovation center give Amgen relative to peers such as Johnson & Johnson, Pfizer, and GSK? How will the $600 million R&D investment affect Amgen’s earnings guidance and valuation multiples?
R&d
8 days ago
Read more prnewswire

REPATHA® NOW INDICATED FOR ADULTS AT INCREASED RISK FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS DUE TO UNCONTROLLED LDL-C

THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to ...

Will the new indication lead to changes in pricing, reimbursement, or insurance coverage that could influence the drug's adoption rate? What is the expected impact of the broader FDA approval on Repatha's market share versus competing PCSK9 inhibitors and statins? How will the expanded indication for Repatha affect Amgen's revenue forecasts and earnings guidance?
Regulatory
16 days ago
Read more prnewswire